MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells. Issue 1 (21st May 2019)
- Record Type:
- Journal Article
- Title:
- MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells. Issue 1 (21st May 2019)
- Main Title:
- MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
- Authors:
- Stutvoet, Thijs S
Kol, Arjan
de Vries, Elisabeth GE
de Bruyn, Marco
Fehrmann, Rudolf SN
Terwisscha van Scheltinga, Anton GT
de Jong, Steven - Abstract:
- Abstract: Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have improved the survival of patients with non‐small cell lung cancer (NSCLC). Still, many patients do not respond to these inhibitors. PD‐L1 ( CD274 ) expression, one of the factors that influences the efficacy of immune checkpoint inhibitors, is dynamic. Here, we studied the regulation of PD‐L1 expression in NSCLC without targetable genetic alterations in EGFR, ALK, BRAF, ROS1, MET, ERBB2 and RET . Analysis of RNA sequencing data from these NSCLCs revealed that inferred IFNγ, EGFR and MAPK signaling correlated with CD274 gene expression in lung adenocarcinoma. In a representative lung adenocarcinoma cell line panel, stimulation with EGF or IFNγ increased CD274 mRNA and PD‐L1 protein and membrane levels, which were further enhanced by combining EGF and IFNγ. Similarly, tumor cell PD‐L1 membrane levels increased after coculture with activated peripheral blood mononuclear cells. Inhibition of the MAPK pathway, using EGFR inhibitors cetuximab and erlotinib or the MEK 1 and 2 inhibitor selumetinib, prevented EGF‐ and IFNγ‐induced CD274 mRNA and PD‐L1 protein and membrane upregulation, but had no effect on IFNγ‐induced MHC‐I upregulation. Interestingly, although IFNγ increases transcriptional activity of CD274, MAPK signaling also increased stabilization of CD274 mRNA. In conclusion, MAPK pathway activity plays a key role in EGF‐ and IFNγ‐induced PD‐L1Abstract: Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have improved the survival of patients with non‐small cell lung cancer (NSCLC). Still, many patients do not respond to these inhibitors. PD‐L1 ( CD274 ) expression, one of the factors that influences the efficacy of immune checkpoint inhibitors, is dynamic. Here, we studied the regulation of PD‐L1 expression in NSCLC without targetable genetic alterations in EGFR, ALK, BRAF, ROS1, MET, ERBB2 and RET . Analysis of RNA sequencing data from these NSCLCs revealed that inferred IFNγ, EGFR and MAPK signaling correlated with CD274 gene expression in lung adenocarcinoma. In a representative lung adenocarcinoma cell line panel, stimulation with EGF or IFNγ increased CD274 mRNA and PD‐L1 protein and membrane levels, which were further enhanced by combining EGF and IFNγ. Similarly, tumor cell PD‐L1 membrane levels increased after coculture with activated peripheral blood mononuclear cells. Inhibition of the MAPK pathway, using EGFR inhibitors cetuximab and erlotinib or the MEK 1 and 2 inhibitor selumetinib, prevented EGF‐ and IFNγ‐induced CD274 mRNA and PD‐L1 protein and membrane upregulation, but had no effect on IFNγ‐induced MHC‐I upregulation. Interestingly, although IFNγ increases transcriptional activity of CD274, MAPK signaling also increased stabilization of CD274 mRNA. In conclusion, MAPK pathway activity plays a key role in EGF‐ and IFNγ‐induced PD‐L1 expression in lung adenocarcinoma without targetable genetic alterations and may present a target to improve the efficacy of immunotherapy. © 2019 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. … (more)
- Is Part Of:
- Journal of pathology. Volume 249:Issue 1(2019)
- Journal:
- Journal of pathology
- Issue:
- Volume 249:Issue 1(2019)
- Issue Display:
- Volume 249, Issue 1 (2019)
- Year:
- 2019
- Volume:
- 249
- Issue:
- 1
- Issue Sort Value:
- 2019-0249-0001-0000
- Page Start:
- 52
- Page End:
- 64
- Publication Date:
- 2019-05-21
- Subjects:
- non‐small cell lung cancer (NSCLC) -- programmed death‐ligand 1 (PD‐L1) -- IFNγ -- MAPK pathway -- MHC‐I
Pathology -- Periodicals
616.07 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/path.5280 ↗
- Languages:
- English
- ISSNs:
- 0022-3417
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5029.900000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 23016.xml